Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Cormedix Inc has a consensus price target of $15.63 based on the ratings of 8 analysts. The high is $19 issued by JMP Securities on April 9, 2024. The low is $12 issued by RBC Capital on March 26, 2025. The 3 most-recent analyst ratings were released by Needham, D. Boral Capital, and Needham on May 7, 2025, May 6, 2025, and April 9, 2025, respectively. With an average price target of $14 between Needham, D. Boral Capital, and Needham, there's an implied 2.26% upside for Cormedix Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/07/2025 | Buy Now | 9.57% | Needham | Serge Belanger68% | $12 → $15 | Maintains | Buy | Get Alert |
05/06/2025 | Buy Now | 9.57% | D. Boral Capital | Jason Kolbert54% | $15 → $15 | Maintains | Buy | Get Alert |
04/09/2025 | Buy Now | -12.34% | Needham | Serge Belanger68% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
04/08/2025 | Buy Now | 9.57% | D. Boral Capital | Jason Kolbert54% | $15 → $15 | Maintains | Buy | Get Alert |
03/26/2025 | Buy Now | -12.34% | RBC Capital | Gregory Renza50% | $12 → $12 | Reiterates | Outperform → Outperform | Get Alert |
03/26/2025 | Buy Now | -12.34% | Needham | Serge Belanger68% | $18 → $12 | Maintains | Buy | Get Alert |
03/25/2025 | Buy Now | 9.57% | D. Boral Capital | Jason Kolbert54% | $15 → $15 | Maintains | Buy | Get Alert |
03/07/2025 | Buy Now | 31.48% | Leerink Partners | Roanna Ruiz37% | → $18 | Initiates | → Outperform | Get Alert |
03/05/2025 | Buy Now | 9.57% | D. Boral Capital | Jason Kolbert54% | $15 → $15 | Maintains | Buy | Get Alert |
01/22/2025 | Buy Now | 9.57% | D. Boral Capital | Jason Kolbert54% | $15 → $15 | Maintains | Buy | Get Alert |
01/13/2025 | Buy Now | 9.57% | D. Boral Capital | Jason Kolbert54% | → $15 | Initiates | → Buy | Get Alert |
12/19/2024 | Buy Now | -12.34% | RBC Capital | Gregory Renza50% | $11 → $12 | Maintains | Outperform | Get Alert |
10/31/2024 | Buy Now | 31.48% | Needham | Serge Belanger68% | $10 → $18 | Maintains | Buy | Get Alert |
10/22/2024 | Buy Now | 24.18% | Truist Securities | Joon Lee76% | $12 → $17 | Maintains | Buy | Get Alert |
08/26/2024 | Buy Now | -5.04% | Rodman & Renshaw | Brandon Folkes43% | → $13 | Initiates | → Buy | Get Alert |
08/15/2024 | Buy Now | -34.26% | RBC Capital | Gregory Renza50% | $9 → $9 | Reiterates | Outperform → Outperform | Get Alert |
08/15/2024 | Buy Now | -26.95% | Needham | Serge Belanger68% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
07/25/2024 | Buy Now | -12.34% | Truist Securities | Joon Lee76% | $14 → $12 | Maintains | Buy | Get Alert |
06/19/2024 | Buy Now | -26.95% | Needham | Serge Belanger68% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
05/13/2024 | Buy Now | -26.95% | Needham | Serge Belanger68% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
04/09/2024 | Buy Now | -26.95% | Needham | Serge Belanger68% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
04/09/2024 | Buy Now | 38.79% | JMP Securities | Jason Butler52% | → $19 | Reiterates | Market Outperform → Market Outperform | Get Alert |
03/13/2024 | Buy Now | -34.26% | RBC Capital | Gregory Renza50% | $10 → $9 | Maintains | Outperform | Get Alert |
03/12/2024 | Buy Now | -26.95% | Needham | Serge Belanger68% | $10 → $10 | Maintains | Buy | Get Alert |
01/31/2024 | Buy Now | 2.26% | Truist Securities | Joon Lee76% | $18 → $14 | Maintains | Buy | Get Alert |
11/15/2023 | Buy Now | -26.95% | Needham | Serge Belanger68% | $12 → $10 | Maintains | Buy | Get Alert |
11/15/2023 | Buy Now | -26.95% | RBC Capital | Gregory Renza50% | $6 → $10 | Maintains | Outperform | Get Alert |
11/15/2023 | Buy Now | 31.48% | Truist Securities | Joon Lee76% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
11/15/2023 | Buy Now | 38.79% | JMP Securities | Jason Butler52% | → $19 | Reiterates | Market Outperform → Market Outperform | Get Alert |
08/10/2023 | Buy Now | -56.17% | RBC Capital | Gregory Renza50% | → $6 | Initiates | → Outperform | Get Alert |
08/08/2023 | Buy Now | -12.34% | Needham | Serge Belanger68% | $13 → $12 | Maintains | Buy | Get Alert |
06/21/2023 | Buy Now | -5.04% | Needham | Serge Belanger68% | → $13 | Reiterates | Buy → Buy | Get Alert |
05/19/2023 | Buy Now | 38.79% | JMP Securities | Jason Butler52% | $16 → $19 | Maintains | Market Outperform | Get Alert |
05/16/2023 | Buy Now | -5.04% | Needham | Serge Belanger68% | → $13 | Reiterates | Buy → Buy | Get Alert |
03/31/2023 | Buy Now | 16.87% | JMP Securities | Jason Butler52% | → $16 | Reiterates | → Market Outperform | Get Alert |
03/31/2023 | Buy Now | -5.04% | Needham | Serge Belanger68% | → $13 | Reiterates | → Buy | Get Alert |
03/03/2023 | Buy Now | -5.04% | Needham | Serge Belanger68% | → $13 | Reiterates | → Buy | Get Alert |
03/01/2023 | Buy Now | 16.87% | JMP Securities | Roy Buchanan42% | $14 → $16 | Maintains | Market Perform | Get Alert |
11/11/2022 | Buy Now | -5.04% | Needham | Serge Belanger68% | $12 → $13 | Maintains | Buy | Get Alert |
08/12/2022 | Buy Now | 16.87% | Truist Securities | Joon Lee76% | $27 → $16 | Maintains | Buy | Get Alert |
08/09/2022 | Buy Now | 2.26% | JMP Securities | Jason Butler52% | $19 → $14 | Maintains | Market Outperform | Get Alert |
08/09/2022 | Buy Now | -12.34% | Needham | Serge Belanger68% | $20 → $12 | Maintains | Buy | Get Alert |
The latest price target for Cormedix (NASDAQ:CRMD) was reported by Needham on May 7, 2025. The analyst firm set a price target for $15.00 expecting CRMD to rise to within 12 months (a possible 9.57% upside). 18 analyst firms have reported ratings in the last year.
The latest analyst rating for Cormedix (NASDAQ:CRMD) was provided by Needham, and Cormedix maintained their buy rating.
There is no last upgrade for Cormedix
There is no last downgrade for Cormedix.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cormedix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cormedix was filed on May 7, 2025 so you should expect the next rating to be made available sometime around May 7, 2026.
While ratings are subjective and will change, the latest Cormedix (CRMD) rating was a maintained with a price target of $12.00 to $15.00. The current price Cormedix (CRMD) is trading at is $13.69, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.